Vitality Biopharma Discovers and Patents Use of Cannabinoids for C.diff-Associated Diarrhea and Colitis
10 mai 2018 08h30 HE
|
Vitality Biopharma, Inc
- Vitality’s GI-targeted VBX-100 THC compound to be investigated as treatment of recurrent C. difficile infections LOS ANGELES, May 10, 2018 (GLOBE NEWSWIRE) -- Vitality Biopharma, Inc....